arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2016-22-3-232-243arthyper-429Research ArticleОБЗОРREVIEWСовременные представления о роли липопротеина (а) в развитии сердечно-сосудистых событий. Возможности терапииThe role of lipoprotein (a) in the development of cardiovascular events and the therapeutic potentialЗуеваИ. Б.ZuevaI. B.

доктор медицинских наук, руководитель группы когнитивных нарушений ФГБУ «СЗФМИЦ им. В. А. Алмазова» Минздрава России

MD, Head, Group of Cognitive Impairment, V. A. Almazov North-West Federal Medical Research Centre

iravit@yandex.ruБараташвилиГ. Г.BaratashviliG. G.

кандидат медицинских наук, заведующий отделением клинической трансфузиологии ФГБУ «СЗФМИЦ им. В. А. Алмазова» Минздрава России

PhD, Head, Department of Clinical Transfusiology, V. A. Almazov North-West Federal Medical Research Centre

КривоносовД. С.KrivonosovD. S.

кандидат медицинских наук, научный сотрудник группы когнитивных нарушений ФГБУ «СЗФМИЦ им. В. А. Алмазова» Минздрава России

PhD, Researcher, Group of Cognitive Impairment, V. A. Almazov North-West Federal Medical Research Centre

БучА. В.BuchA. V.

врач-кардиолог отделения кардиологии № 6 ФГБУ «СЗФМИЦ им. В. А. Алмазова» Минздрава России

Cardiologist, Department of Cardiology № 6, V. A. Almazov North-West Federal Medical Research Centre

СидоркевичС. В.SidorkevichS. V.

доктор медицинских наук, главный врач станции переливания крови, заведующий НИЛ трансфузиологии и эфферентной терапии ФГБУ «СЗФМИЦ им. В. А. Алмазова» Минздрава России

MD, Head Physician, Station of Blood Transfusion, Head, Research Laboratory of Transfusion and Efferent Therapy, V. A. Almazov North-West Federal Medical Research Centre

Федеральное государственное бюджетное учреждение «Северо-Западный федеральный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации, Санкт-Петербург, Россия ул. Аккуратова, д. 2, Санкт-Петербург, Россия, 197341. Тел.: +7 (812)702–68–11РоссияV. A. Almazov Federal North-West Medical Research Centre, St Petersburg, Russia 2 Akkuratov street, St Petersburg, 197341 Russia. Phone: +7 (812)702–68–11Russian FederationФедеральное государственное бюджетное учреждение «Северо-Западный федеральный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации, Санкт-Петербург, РоссияРоссияV. A. Almazov Federal North-West Medical Research Centre, St Petersburg, RussiaRussian Federation201622082016223232243Copyright © Зуева И.Б., Бараташвили Г.Г., Кривоносов Д.С., Буч А.В., Сидоркевич С.В., 20162016Зуева И.Б., Бараташвили Г.Г., Кривоносов Д.С., Буч А.В., Сидоркевич С.В.Zueva I.B., Baratashvili G.G., Krivonosov D.S., Buch A.V., Sidorkevich S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/429

Несмотря на адекватную гиполипидемическую терапию, сохраняется высокий риск сердечно-сосудистых осложнений. Одним из основных факторов, оказывающих влияние на резидуальный риск у пациентов с атерогенной дислипидемией наряду с повышенным уровнем триглицеридов и сниженным уровнем холестерина липопротеинов высокой плотности, является липопротеин (а). В обзоре подробно освещены современные представления о влиянии липопротеина (а) на развитие и прогрессирование атеросклероза, а также основные методы лечения

Despite adequate lipid-lowering therapy the rate of cardiovascular complications is still high. One of the main factors influencing the residual risk in patients with atherogenic dyslipidemia, along with elevated triglycerides and reduced cholesterol of high density lipoproteins is lipoprotein (a). The paper reviews the current conception of the impact of lipoprotein (a) on the development and progression of atherosclerosis, as well as the main methods of treatment, including lipid apheresis.

липопротеин (а)гиполипидемическая терапиялипидаферезlipoprotein (a)lipid-lowering therapylipid apheresisReferencesЗубарева М. Ю., Сусеков А. В. Программа снижения остаточного (резидуального) сосудистого риска: проект R3i (the Residual Risk Reduction Initiative). Часть I. Факторы остаточного риска. Кардиология. 2010;50 (8):76–83. [Zubarev MY, Susekov AV. Reduction program residual (residual) vascular risk: the R3i project (the Residual Risk Reduction Initiative). Part I. risk Factors of residual. Kardiologiia. 2010;50(8):76–83. In Russian].Зубарева М. Ю., Сусеков А. В. Программа снижения остаточного (резидуального) сосудистого риска: проект R3i (the Residual Risk Reduction Initiative). Часть I. Факторы остаточного риска. Кардиология. 2010;50 (8):76–83. [Zubarev MY, Susekov AV. Reduction program residual (residual) vascular risk: the R3i project (the Residual Risk Reduction Initiative). Part I. risk Factors of residual. Kardiologiia. 2010;50(8):76–83. In Russian].Anping Cai, Liwen Li, Zhang Y. Lipoprotein (a): a promising marker for residual cardiovascular risk assessment. Dis Markers. 2013;35(5):551–559.Anping Cai, Liwen Li, Zhang Y. Lipoprotein (a): a promising marker for residual cardiovascular risk assessment. Dis Markers. 2013;35(5):551–559.Fruchart JC, Sacks FM, Hermans MP. The residual risk reduction initiative: a call to action to reduce residual risk in dyslipideamic patients. Diab Vasc Dis Res. 2010;2:319–335.Fruchart JC, Sacks FM, Hermans MP. The residual risk reduction initiative: a call to action to reduce residual risk in dyslipideamic patients. Diab Vasc Dis Res. 2010;2:319–335.Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S. Lipoprotein (a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129(6):635–642.Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S. Lipoprotein (a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129(6):635–642.Koschinsky M, Marcovina SM. Lipoprotin (a). In: C. Ballantyne, ed. Clinical lipidology: a companion to Braunwald’s heart disease. Philadelphia: Saunders Elsevier, 2009. P. 130–143.Koschinsky M, Marcovina SM. Lipoprotin (a). In: C. Ballantyne, ed. Clinical lipidology: a companion to Braunwald’s heart disease. Philadelphia: Saunders Elsevier, 2009. P. 130–143.Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein (a), fibrin binding, and plasminogen activation. Arteriosclerosis. 1990;10 (2):240–245.Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein (a), fibrin binding, and plasminogen activation. Arteriosclerosis. 1990;10 (2):240–245.Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute workshop on lipoprotein (a) and cardiovascular disease: recent advances and future directions. Clin Chem. 2003;49(11):1785–1796.Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute workshop on lipoprotein (a) and cardiovascular disease: recent advances and future directions. Clin Chem. 2003;49(11):1785–1796.Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR et al. Associations between lipoprotein (a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation.12;125(2):241–249.Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR et al. Associations between lipoprotein (a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation.12;125(2):241–249.Ezhov MV, Safarova MS, Afanasieva OI, Kukharchuk VV, Pokrovsky SN. Lipoprotein (a) level and apolipoprotein (a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis. 2014;235 (2):477–482.Ezhov MV, Safarova MS, Afanasieva OI, Kukharchuk VV, Pokrovsky SN. Lipoprotein (a) level and apolipoprotein (a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis. 2014;235 (2):477–482.Tsimikas S, Hall JL. Lipoprotein (a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60(8):716–721.Tsimikas S, Hall JL. Lipoprotein (a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60(8):716–721.Ezov MV, Afanasieva OI, Adamova L. Lipoprotein (a) levels predict myocardial infarction in yang men. Atherosclerosis. 2000;51(1):304.Ezov MV, Afanasieva OI, Adamova L. Lipoprotein (a) levels predict myocardial infarction in yang men. Atherosclerosis. 2000;51(1):304.Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации Комитета экспертов Всероссийского научного общества кардиологов. М.: Медицина, 2004. 36 c. [Diagnosis and correction of lipid metabolism disorders prevention and treatment of atherosclerosis. Russian recommendations of the Committee of experts of the Russian scientific society of cardiology. Moscow: Medicine, 2004. 36 p. In Russian].Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации Комитета экспертов Всероссийского научного общества кардиологов. М.: Медицина, 2004. 36 c. [Diagnosis and correction of lipid metabolism disorders prevention and treatment of atherosclerosis. Russian recommendations of the Committee of experts of the Russian scientific society of cardiology. Moscow: Medicine, 2004. 36 p. In Russian].Murase T, Okubo M, Amemiya-Kudo M. Impact of markedly elevated serum lipoprotein (a) levels on the risk of coronary heart disease. Metabolism. 2007;56(9):1187–1191.Murase T, Okubo M, Amemiya-Kudo M. Impact of markedly elevated serum lipoprotein (a) levels on the risk of coronary heart disease. Metabolism. 2007;56(9):1187–1191.Jayasinghe R, Craig IH, Mohan RKA. Lipoprotein (a) in clinical practice. J Pak Med Assoc. 2014;64 (4):447–450.Jayasinghe R, Craig IH, Mohan RKA. Lipoprotein (a) in clinical practice. J Pak Med Assoc. 2014;64 (4):447–450.Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. J Am Med Assoc. 2009;301 (22):2331–2339.Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. J Am Med Assoc. 2009;301 (22):2331–2339.Graham MJ, Viney N, Crooke RM, Tsimikas S. Antisens e inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2016;57(3):340–351.Graham MJ, Viney N, Crooke RM, Tsimikas S. Antisens e inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2016;57(3):340–351.Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on lipoprotein (a) and cardiovascular disease: recent advances and future directions. Clinical Chemistry. 2003;49 (11):1785–1796.Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on lipoprotein (a) and cardiovascular disease: recent advances and future directions. Clinical Chemistry. 2003;49 (11):1785–1796.Ежов М. В., Сафарова М. С., Мальчин Ю. Г., Соболева Д. И., Афанасьева О. И., Покровский С. Н. Связь высокого уровня липопротеина (а) с проходимостью коронарных артерий в течение первого года после чрескожных коронарных вмешательств. Клиницист. 2011;1:18–24. [Ezhov MV, Safarova MS, Malchin YG, Sobolev DI, Afanasуeva OI, Pokrovsky SN. Communication high level of lipoprotein (a) patency of the coronary arteries within the first year after percutaneous coronary interventions. Klinitsist = Clinician. 2011;1:18–24. In Russian].Ежов М. В., Сафарова М. С., Мальчин Ю. Г., Соболева Д. И., Афанасьева О. И., Покровский С. Н. Связь высокого уровня липопротеина (а) с проходимостью коронарных артерий в течение первого года после чрескожных коронарных вмешательств. Клиницист. 2011;1:18–24. [Ezhov MV, Safarova MS, Malchin YG, Sobolev DI, Afanasуeva OI, Pokrovsky SN. Communication high level of lipoprotein (a) patency of the coronary arteries within the first year after percutaneous coronary interventions. Klinitsist = Clinician. 2011;1:18–24. In Russian].National Association of Statutory Health Insurance Physicians (KBV Qualitätsbericht). Quality report. 2013;47–48 [In German].National Association of Statutory Health Insurance Physicians (KBV Qualitätsbericht). Quality report. 2013;47–48 [In German].Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR et al. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke and non-vascular mortality. Emerging risk factors collaboration. J Am Med Assoc. 2009;302 (4):412–423Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR et al. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke and non-vascular mortality. Emerging risk factors collaboration. J Am Med Assoc. 2009;302 (4):412–423Bennet A, Di AE, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M et al. Lipoprotein (a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med. 2008;168(6):598–608.Bennet A, Di AE, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M et al. Lipoprotein (a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med. 2008;168(6):598–608.Ежов М. В., Сафарова М. С., Афанасьева О. И., Ильина Л. Н., Лякишев А. А., Покровский С. Н. Липопротеин (а) как предиктор неблагоприятного прогноза в отдаленные сроки после операции коронарного шунтирования. Кардиология. 2011;51(1):18–22. [Ezhov VM, Safarova MS, Afanasieva OI, Il’уna LN, Lyakishev AA, Pokrovskiy SN. Lipoprotein (a) as a predictor of adverse prognosis in long-term periods after coronary bypass surgery. Kardiologiia. 2011;51(1):18–22. In Russian].Ежов М. В., Сафарова М. С., Афанасьева О. И., Ильина Л. Н., Лякишев А. А., Покровский С. Н. Липопротеин (а) как предиктор неблагоприятного прогноза в отдаленные сроки после операции коронарного шунтирования. Кардиология. 2011;51(1):18–22. [Ezhov VM, Safarova MS, Afanasieva OI, Il’уna LN, Lyakishev AA, Pokrovskiy SN. Lipoprotein (a) as a predictor of adverse prognosis in long-term periods after coronary bypass surgery. Kardiologiia. 2011;51(1):18–22. In Russian].Holmes DT, Schick BA, Humphries KH, Frohlich J. Lipoprotein (a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem. 2005;51(11):2067– 2073.Holmes DT, Schick BA, Humphries KH, Frohlich J. Lipoprotein (a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem. 2005;51(11):2067– 2073.Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004;256(6):482–490.Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004;256(6):482–490.Albers JJ, Slee A, O’Brien KD. Relatiohship of Apolipoproteins A‑1 and B, and Lipoprotein (a) to cardio-vascular outcomes: the AIM-HIGH trial. J Am Coll Cardiol. 2013;62 (17):1575–1579.Albers JJ, Slee A, O’Brien KD. Relatiohship of Apolipoproteins A‑1 and B, and Lipoprotein (a) to cardio-vascular outcomes: the AIM-HIGH trial. J Am Coll Cardiol. 2013;62 (17):1575–1579.Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein (a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63(5):470–477.Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein (a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63(5):470–477.Герасимов A. M., Черкавская О. В., Масленников М. А., Кочетов А. Клеточные механизмы, клинические и морфологические факторы риска развития рестеноза. Вестн. рентгенол. радиол. 2011;4:58–65. [Gerasimov AM, Czerkawska OV, Maslennikov MA, Kochetov A. Cellular mechanisms, clinical and morphological risk factors for the development of restenosis.Vestnik Rentgenologii i Radiologii = Bulletin of Roentgenology and Radiology. 2011;4:58–65. In Russian].Герасимов A. M., Черкавская О. В., Масленников М. А., Кочетов А. Клеточные механизмы, клинические и морфологические факторы риска развития рестеноза. Вестн. рентгенол. радиол. 2011;4:58–65. [Gerasimov AM, Czerkawska OV, Maslennikov MA, Kochetov A. Cellular mechanisms, clinical and morphological risk factors for the development of restenosis.Vestnik Rentgenologii i Radiologii = Bulletin of Roentgenology and Radiology. 2011;4:58–65. In Russian].Morita Y, Himeno H, Yakuwa H, Usui T. Serum lipoprotein (a) level and clinical coronary stenosis progression in patients with myocardial infarction: re-revascularization rate is high in patients with high-Lp (a). Circ J. 2006;70(2):156–162.Morita Y, Himeno H, Yakuwa H, Usui T. Serum lipoprotein (a) level and clinical coronary stenosis progression in patients with myocardial infarction: re-revascularization rate is high in patients with high-Lp (a). Circ J. 2006;70(2):156–162.Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI et al. The impact of plasma levels of C‑reactive protein, lipoprotein (a) and homocysteine on the longterm prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol. 2002;40(8):1375–1382.Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI et al. The impact of plasma levels of C‑reactive protein, lipoprotein (a) and homocysteine on the longterm prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol. 2002;40(8):1375–1382.Harpel PC, Haque NS. Chemokine receptor‑8: potential role in atherogenesis. Isr Med Assoc J. 2002;4(11):1025–1027.Harpel PC, Haque NS. Chemokine receptor‑8: potential role in atherogenesis. Isr Med Assoc J. 2002;4(11):1025–1027.Haque NS, Zhang X, French DL, Li J, Poon M, Fallon JT et al. CC chemokine I‑309 is the principal monocyte chemoattractant induced by apolipoprotein (a) in human vascular endothelial cells. Circulation. 2000;102(7):786–792.Haque NS, Zhang X, French DL, Li J, Poon M, Fallon JT et al. CC chemokine I‑309 is the principal monocyte chemoattractant induced by apolipoprotein (a) in human vascular endothelial cells. Circulation. 2000;102(7):786–792.Poon MI, Zhang X, Dunsky K, Taubman MB, Harpel PC. Apolipoprotein (a) is a human vascular endothelial cell agonist: studies on the induction in endothelial cells of monocyte chemotactic factor activity. Clin Genet. 1997;52(5):308–313.Poon MI, Zhang X, Dunsky K, Taubman MB, Harpel PC. Apolipoprotein (a) is a human vascular endothelial cell agonist: studies on the induction in endothelial cells of monocyte chemotactic factor activity. Clin Genet. 1997;52(5):308–313.Lucas AD, Greaves DR. Atherosclerosis: role of chemokines and macrophages. Expert Rev Mol Med. 2001;3(25):1–18.Lucas AD, Greaves DR. Atherosclerosis: role of chemokines and macrophages. Expert Rev Mol Med. 2001;3(25):1–18.Tsimikas SI, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein (a) atherogenicity. Curr Opin Lipidol. 2008;19(4):369–377.Tsimikas SI, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein (a) atherogenicity. Curr Opin Lipidol. 2008;19(4):369–377.Владимирская Т. Э., Швед И. А., Криворот С. Г. Морфологические изменения и апоптоз эндотелиальных клеток коронарных артерий при атеросклерозе. Кардиология. 2014;12:44– 46. [Vladimirskaya TE, Shved IA, Kryvorot SG. Morphological changes and apoptosis of endothelial cells of the coronary arteries in atherosclerosis. Kardiologiia. 2014;12:44–46. In Russian].Владимирская Т. Э., Швед И. А., Криворот С. Г. Морфологические изменения и апоптоз эндотелиальных клеток коронарных артерий при атеросклерозе. Кардиология. 2014;12:44– 46. [Vladimirskaya TE, Shved IA, Kryvorot SG. Morphological changes and apoptosis of endothelial cells of the coronary arteries in atherosclerosis. Kardiologiia. 2014;12:44–46. In Russian].Hervio L, Girard-Globa A, Durlach V, Anglés-Cano E. The antifibrinolytic effect of Lipoprotein (a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein (a) isoforms and their affinity for fibrin. Eur J Clin Invest. 1996;26 (5):411–417.Hervio L, Girard-Globa A, Durlach V, Anglés-Cano E. The antifibrinolytic effect of Lipoprotein (a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein (a) isoforms and their affinity for fibrin. Eur J Clin Invest. 1996;26 (5):411–417.Lawn RM, Pearle AD, Kunz LL, Rubin EM, Reckless J, Metcalfe JC et al. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein (a) mice. J Biol Chem. 1996;271(49):31367–31371.Lawn RM, Pearle AD, Kunz LL, Rubin EM, Reckless J, Metcalfe JC et al. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein (a) mice. J Biol Chem. 1996;271(49):31367–31371.Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor‑1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem. 1991;266(4):2459–2465.Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor‑1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem. 1991;266(4):2459–2465.Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126(3):314–345.Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126(3):314–345.Pan J, Lin M, Kesala RL, Van J, Charles MA. Niacin treatment of the atherogenic lipid profile and Lp (a) in diabetes. Diabetes Obes Metab. 2002;4(4):255–261.Pan J, Lin M, Kesala RL, Van J, Charles MA. Niacin treatment of the atherogenic lipid profile and Lp (a) in diabetes. Diabetes Obes Metab. 2002;4(4):255–261.HPS2‑THRIVE Collaborative Group. HPS2‑THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279–1291.HPS2‑THRIVE Collaborative Group. HPS2‑THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279–1291.Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013;35(8):1082–1098.Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013;35(8):1082–1098.Aronow WS. PCSK9 Inhibitors. Cardiovasc Pharm Open Access. 2015;4:4.Aronow WS. PCSK9 Inhibitors. Cardiovasc Pharm Open Access. 2015;4:4.Kastelein JJP, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK et al. Anacetrapib as lipid- modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015;385(9983):2153–2161.Kastelein JJP, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK et al. Anacetrapib as lipid- modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015;385(9983):2153–2161.Bos S, Yayha R, van Lennep JE. Latest developments in the treatment of lipoprotein (a). Curr Opin Lipidol. 2014;25 (6):452–460.Bos S, Yayha R, van Lennep JE. Latest developments in the treatment of lipoprotein (a). Curr Opin Lipidol. 2014;25 (6):452–460.Kyutoku M, Nakagami H, Koriyama H, Nakagami F, Shimamura M, Kurinami H et al. Inhibition of neointima formation through DNA vaccination for apolipoprotein (a): a new therapeutic strategy for lipoprotein (a). Sci Rep. 2013;3:1600.Kyutoku M, Nakagami H, Koriyama H, Nakagami F, Shimamura M, Kurinami H et al. Inhibition of neointima formation through DNA vaccination for apolipoprotein (a): a new therapeutic strategy for lipoprotein (a). Sci Rep. 2013;3:1600.Khan TZ, Pottle A, Pennell DJ, Barbir MS. The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein (a) in ischaemic heart disease and refractory angina. Glob Cardiol Sci Pract. 2014;29(1):3–12.Khan TZ, Pottle A, Pennell DJ, Barbir MS. The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein (a) in ischaemic heart disease and refractory angina. Glob Cardiol Sci Pract. 2014;29(1):3–12.Borberg H. Comparison of different Lp (a) elimination techniques: a retrospective evaluation. Transfus Apher Sci. 2009;41 (1):61–65.Borberg H. Comparison of different Lp (a) elimination techniques: a retrospective evaluation. Transfus Apher Sci. 2009;41 (1):61–65.Лопухин Ю. М., Арчаков А. И., Владимиров Ю. А., Коган Э. М. Холестериноз. М.: Медицина, 1983. 352 с. [Lopukhin YuM, Archakov AI, Vladimirov YA, Kogan EM. Cholesterinosis. Moscow: Medicine, 1983. 352 p. In Russian].Лопухин Ю. М., Арчаков А. И., Владимиров Ю. А., Коган Э. М. Холестериноз. М.: Медицина, 1983. 352 с. [Lopukhin YuM, Archakov AI, Vladimirov YA, Kogan EM. Cholesterinosis. Moscow: Medicine, 1983. 352 p. In Russian].Bosch T. Therapeutic apheresis — state of the art in the year 2005. Therapeutic Apheresis and Dialysis. 2005;9(6):459–468.Bosch T. Therapeutic apheresis — state of the art in the year 2005. Therapeutic Apheresis and Dialysis. 2005;9(6):459–468.Hovland A, Marcovina S, Hardersen R, Enebakk T, Mollnes TE, Lappegård KT. et al. Three different LDL apheresis columns efficiently and equally reduce lipoprotein (a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein (a) particles. J Clin Apher. 2012;46(1):73–76.Hovland A, Marcovina S, Hardersen R, Enebakk T, Mollnes TE, Lappegård KT. et al. Three different LDL apheresis columns efficiently and equally reduce lipoprotein (a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein (a) particles. J Clin Apher. 2012;46(1):73–76.Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D et al. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL — or Lp (a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. Atheroscler Suppl. 2015;18:154–162.Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D et al. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL — or Lp (a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. Atheroscler Suppl. 2015;18:154–162.Borberg H. 26 Years of LDL — Apheresis: a review of experience transfusion and apheresis. Science. 2009;41(1):49–59.Borberg H. 26 Years of LDL — Apheresis: a review of experience transfusion and apheresis. Science. 2009;41(1):49–59.Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis. 2010;208(2):317–321.Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis. 2010;208(2):317–321.Emmrich U, Hohenstein B, Julius U. Actual situation of lipoprotein apheresis in Saxony in 2013. Atheroscler Suppl. 2015;18:215–225.Emmrich U, Hohenstein B, Julius U. Actual situation of lipoprotein apheresis in Saxony in 2013. Atheroscler Suppl. 2015;18:215–225.Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E et al. Group of clinical investigators longitudinal cohort study on the effectiveness of apheresis treatment to reduce high lipoprotein (a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6(3):229–239.Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E et al. Group of clinical investigators longitudinal cohort study on the effectiveness of apheresis treatment to reduce high lipoprotein (a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6(3):229–239.Heigl F, Hettich R, Lotz N, Reeg H, Pfledere T, Osterkorn D et al. Clinical benefit of long-term lipoprtein apheresis in patients with severe hypercholesterolemia. Clin Res Cardiol Suppl. 2015;10:8– 13.Heigl F, Hettich R, Lotz N, Reeg H, Pfledere T, Osterkorn D et al. Clinical benefit of long-term lipoprtein apheresis in patients with severe hypercholesterolemia. Clin Res Cardiol Suppl. 2015;10:8– 13.Klingel R, Heibges A, Fassbender C. Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro (a) LiFe study. Clin Res Cardiol Suppl. 2015;10 (Suppl):46–50.Klingel R, Heibges A, Fassbender C. Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro (a) LiFe study. Clin Res Cardiol Suppl. 2015;10 (Suppl):46–50.Сусеков А. В., Афанасьева О. И., Адамова И. Ю., Якишев А. А., Кухарчук В. В., Покровский С. Н. Применение иммуносорбента для селективного снижения уровня липопротеина (а) у больных с коронарным атеросклерозом. Кардиология. 1993;32:52–56. [Susekov AV, Afanasieva OI, Adamova IY, Akishev AA, Kuharchuk VV, Pokrovsky SN. The use of immunosorbent for selective reduction of lipoprotein (a) in patients with coronary atherosclerosis. Kardiologiia. 1993;32:52– 56. In Russian].Сусеков А. В., Афанасьева О. И., Адамова И. Ю., Якишев А. А., Кухарчук В. В., Покровский С. Н. Применение иммуносорбента для селективного снижения уровня липопротеина (а) у больных с коронарным атеросклерозом. Кардиология. 1993;32:52–56. [Susekov AV, Afanasieva OI, Adamova IY, Akishev AA, Kuharchuk VV, Pokrovsky SN. The use of immunosorbent for selective reduction of lipoprotein (a) in patients with coronary atherosclerosis. Kardiologiia. 1993;32:52– 56. In Russian].Yamaguchi H, Lee YJ, Daida H, Yokoi H, Miyano H, Kanoh T et al. Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL-apheresis angioplasty restenosis trial (L‑ART). Chem Phys Lipids. 1994;67–68:399–403.Yamaguchi H, Lee YJ, Daida H, Yokoi H, Miyano H, Kanoh T et al. Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL-apheresis angioplasty restenosis trial (L‑ART). Chem Phys Lipids. 1994;67–68:399–403.Stefanutti C, Vivenzio A, Di Giacomo S, Mazzarella B, Ferraro PM, Abbolito S et al. Treatment of symptomatic hyperLp (a) lipidaemia with LDL-apheresis vs. usual care. Transfus Apher Sci. 2010;42(1):21–26.Stefanutti C, Vivenzio A, Di Giacomo S, Mazzarella B, Ferraro PM, Abbolito S et al. Treatment of symptomatic hyperLp (a) lipidaemia with LDL-apheresis vs. usual care. Transfus Apher Sci. 2010;42(1):21–26.Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853.Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853.Khan TZ, Pottle A, Pennell DJ, Barbir MS. The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein (a) in ischaemic heart disease and refractory angina. Glob Cardiol Sci Pract. 2014;2014(1):3–12.Khan TZ, Pottle A, Pennell DJ, Barbir MS. The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein (a) in ischaemic heart disease and refractory angina. Glob Cardiol Sci Pract. 2014;2014(1):3–12.Dahlen CG. Lipoprotein (a) in cardiovascular disease: Review article and viewpoint. Atherosclerosis. 1994;108(2):111–126.Dahlen CG. Lipoprotein (a) in cardiovascular disease: Review article and viewpoint. Atherosclerosis. 1994;108(2):111–126.Luc G, Bard JM, Arveiler D. Lipoprotein (a) as a predictor of coronary heart disease: the RIME Study. Atherosclerosis. 2002;163(2):377–384.Luc G, Bard JM, Arveiler D. Lipoprotein (a) as a predictor of coronary heart disease: the RIME Study. Atherosclerosis. 2002;163(2):377–384.Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Lipoprotein (a) interactions with lipid and nonlipid risk actors in early familial coronary artery disease. Arterioscl Thromb Vasc Biol. 1997;17(11):2783–2792.Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Lipoprotein (a) interactions with lipid and nonlipid risk actors in early familial coronary artery disease. Arterioscl Thromb Vasc Biol. 1997;17(11):2783–2792.Langsted A, Kamstrup PR, Nordestgaard BG. Lipoprotein (a): fasting and nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis. 2014;234(1):95–101.Langsted A, Kamstrup PR, Nordestgaard BG. Lipoprotein (a): fasting and nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis. 2014;234(1):95–101.

The authors declare that there are no conflicts of interest present.